Wei Liu

List of Publications by Year
in descending order

40 papers	825 citations	623734 14 h-index	501196 28 g-index
41 all docs	41 docs citations	41 times ranked	1124 citing authors

#	Article	IF	Citations
1	Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. BMC Cancer, 2010, 10, 685.	2.6	115
2	Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by Pâ€glycoprotein. Journal of Pharmaceutical Sciences, 2011, 100, 5007-5017.	3.3	111
3	Oral Cancer Development in Patients with Leukoplakia â€“ Clinicopathological Factors Affecting Outcome. PLoS ONE, 2012, 7, e34773.	2.5	86
4	Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia. International Journal of Cancer, 2013, 132, 868-874.	5.1	67
5	Malignant transformation of oral epithelial dysplasia: clinicopathological risk factors and outcome analysis in a retrospective cohort of 138 cases. Histopathology, 2011, 59, 733-740.	2.9	60
6	Two stem cell markers, ATPâ€binding cassette, G2 subfamily (ABCG2) and BMIâ€1, predict the transformation of oral leukoplakia to cancer. Cancer, 2012, 118, 1693-1700.	4.1	57
7	Cellular uptake and anticancer activity of salvianolic acid B phospholipid complex loaded nanoparticles in head and neck cancer and precancer cells. Colloids and Surfaces B: Biointerfaces, 2016, 147, 65-72.	5.0	41
8	Immunoexpression of Interleukin-22 and Interleukin-23 in Oral and Cutaneous Lichen Planus Lesions: A Preliminary Study. Mediators of Inflammation, 2013, 2013, 1-7.	3.0	37
9	Expression of cancer stem cell markers ALDH1 and Bmi1 in oral erythroplakia and the risk of oral cancer. Journal of Oral Pathology and Medicine, 2013, 42, 148-153.	2.7	36
10	Andrographolideâ€loaded solid lipid nanoparticles enhance antiâ€cancer activity against head and neck cancer and precancerous cells. Oral Diseases, 2022, 28, 142-149.	3.0	22
11	DNA content status using brush biopsy with image cytometry correlated with staging of oral leukoplakia: A preliminary study. Oral Oncology, 2015, 51, 59-63.	1.5	18
12	Cytological study of DNA content and nuclear morphometric analysis for aid in the diagnosis of high-grade dysplasia within oral leukoplakia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 280-285.	0.4	18
13	Bibliometric analysis of research trends and characteristics of oral potentially malignant disorders. Clinical Oral Investigations, 2020, 24, 447-454.	3.0	18
14	DNA aneuploidy with image cytometry for detecting dysplasia and carcinoma in oral potentially malignant disorders: A prospective diagnostic study. Cancer Medicine, 2020, 9, 6411-6420.	2.8	16
15	Potential role of autofluorescence imaging in determining biopsy of oral potentially malignant disorders: A large prospective diagnostic study. Oral Oncology, 2019, 98, 176-179.	1.5	15
16	A novel lncRNA LOLA1 may predict malignant progression and promote migration, invasion, and EMT of oral leukoplakia via the AKT/GSKâ€3Î² pathway. Journal of Cellular Biochemistry, 2021, 122, 1302-1312.	2.6	13
17	Cancer stem cell markers ALDH1 and Bmi1 expression in oral erythroplakia revisited: Implication for driving the process of field cancerization. Journal of Oral Pathology and Medicine, 2020, 49, 96-99.	2.7	10
18	Curcumin nanoemulsions inhibit oral squamous cell carcinoma cell proliferation by <scp>PI3K</scp>/Akt/<scp>mTOR</scp> suppression and <scp>miR</scp>â€199a upregulation: A preliminary study. Oral Diseases, 2023, 29, 3183-3192.	3.0	10

#	Article	IF	Citations
19	Altered expression of CCN1 in oral lichen planus associated with keratinocyte activation and ILâ€1Î², ICAM1, and CCL5 upâ€regulation. Journal of Oral Pathology and Medicine, 2020, 49, 920-925.	2.7	9
20	Current evidence on DNA aneuploidy cytology in noninvasive detection of oral cancer. Oral Oncology, 2020, 101, 104367.	1.5	7
21	Chemopreventive efficacy of salvianolic acid B phospholipid complex loaded nanoparticles against experimental oral carcinogenesis: implication of sustained drug release. Annals of Translational Medicine, 2022, 10, 244-244.	1.7	7
22	Retrospective analysis of oral erythroplakia focused on multiple and multifocal malignant behavior. Oral Diseases, 2019, 25, 1829-1830.	3.0	5
23	Development and validation of a risk model for noninvasive detection of cancer in oral potentially malignant disorders using DNA image cytometry. Cancer Biology and Medicine, 2021, 18, 763-771.	3.0	5
24	The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer. Oral Oncology, 2022, 130, 105924.	1.5	5
25	A bibliometric analysis of the papers on oral potentially malignant disorder in Oral Oncology. Oral Oncology, 2022, 132, 105996.	1.5	5
26	Podoplanin and ABCG2 expression in oral erythroplakia revisited: Potential evidence for cancer stem cells driving the process of field cancerization. Oral Oncology, 2020, 101, 104368.	1.5	4
27	Potential association between oral mucosal nevus and melanoma: A preliminary clinicopathologic study. Oral Diseases, 2020, 26, 1240-1245.	3.0	4
28	<scp>DNA</scp> content abnormality in oral submucous fibrosis concomitant leukoplakia: A preliminary evaluation of the diagnostic and clinical implications. Diagnostic Cytopathology, 2020, 48, 1111-1114.	1.0	3
29	Focus on higher rate of malignant transformation of oral submucous fibrosis and concomitant leukoplakia. Oral Diseases, 2022, 28, 2055-2056.	3.0	3
30	Implications of salivary <scp>miRNAs</scp> for noninvasive diagnosing oral potentially malignant disorders. Oral Diseases, 2024, 30, 796-798.	3.0	3
31	Bibliometric analysis of the topâ€cited articles on oral erythroplakia and leukoplakia. Journal of Oral Pathology and Medicine, 2019, 48, 505-506.	2.7	2
32	Prevalence and risk of chronic kidney disease in oral lichen planus: a large cross-sectional study from eastern China. Annals of Translational Medicine, 2021, 9, 1078-1078.	1.7	2
33	Whether cancer stem cell markers can serve as the markers for malignant progression of oral potentially malignant disorders. Oral Diseases, 2022, 28, 2057-2058.	3.0	2
34	Salivary and serum cytokines as indicators for monitoring therapeutic response of oral lichen planus. Oral Diseases, 2023, 29, 333-335.	3.0	2
35	Clinical investigation on oral lichen planus and associated comorbidities needs a holistic concept. Oral Diseases, 2023, 29, 327-329.	3.0	2
36	Autofluorescence imaging as a noninvasive tool of risk stratification for malignant transformation of oral leukoplakia: A follow-up cohort study. Oral Oncology, 2022, 130, 105941.	1.5	2

#	Article	IF	Citations
37	Contrasting results of DNA content analysis in oral lichen planus. Oral Diseases, 2019, 25, 1674-1675.	3.0	1
38	Relationship of DNA aneuploidy with distinctive features of oral potentially malignant disorders: A cytological analysis of 748 cases. Journal of Dental Sciences, 2021, , .	2.5	1
39	Focus on DNAâ€aneuploidy cytology relationship with dysplasia and clinical features in OPMDs. Oral Diseases, 2022, 28, 1743-1745.	3.0	1
40	Focus on <scp>DNA</scp> methylation in saliva and oral swabs for oral potentially malignant disorder diagnosis. Oral Diseases, 2024, 30, 801-804.	3.0	0